Proactive Investors
02 Jul 2026, 10:36 UTC · 18w ago
Impact · against what's priced in
Jefferies provides bullish catalysts for Computacenter, Plus500, and AstraZeneca, primarily centered on upcoming earnings beats and clinical trial results. The most significant potential move is AstraZeneca's multi-billion dollar opportunity linked to the CARDIO-TTRansform trial readouts.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
AstraZeneca faces two clinical trial readouts in July and August, with the CARDIO-TTRansform trial potentially unlocking a multi-billion dollar opportunity.
More positive than 99% of claims this week
Jefferies identifies Computacenter PLC as a top 'picks and shovels' play for AI spending, with significant exposure to US corporate infrastructure and cloud providers.
Continue reading
5 related stories
Upcoming clinical trial readouts in July and August, specifically the CARDIO-TTRansform trial, represent a potential multi-billion dollar revenue opportunity.
Read from the article alone
No priced-in read yet
Jefferies positions the company as a 'picks and shovels' AI play with significant exposure to US corporate infrastructure and a management goal to increase operating profit conversion from 24% to 30%.
Read from the article alone
No priced-in read yet
High trading volumes and volatility suggest room for a full-year guidance upgrade on July 13, with Jefferies' estimates sitting 6% above market consensus.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 93% of claims this week
Jefferies expects Plus500 Ltd to potentially upgrade full-year guidance on July 13 due to high trading volumes and cautious market forecasts.
More positive than 85% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
Jefferies identifies it as a 'buy' and a preferred way to play AI spending with potential to beat market expectations.
More positive than 89% of ticker scores this week
Jefferies rates it a 'buy' and suggests there is room for an upgrade to full-year guidance due to strong trading volumes.
More positive than 83% of ticker scores this week
Jefferies flags it as a potential winner with a 'buy' rating and high-potential clinical trial readouts pending.
More positive than 69% of ticker scores this week
The company is progressing with its MESH project after receiving a gas storage licence.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
4d ago
+0.3%
Price flat so far
$184.46 vs $183.86 close before publication (Jul 1) · not market-adjusted
AZN chart →+18.6%
Price agrees with the score
$97.67 vs $82.35 close before publication (Jul 1) · not market-adjusted
PLUS chart →+43.3%
Price agrees with the score
$7.71 vs $5.38 close before publication (Jul 1) · not market-adjusted
CCC chart →
